GI Oncology Now

🔎 A review of research led by Aaron J. Scott, MD, of University of Arizona Cancer Center and colleagues found new recommendations for the management of locally advanced #rectalcancer. 📋 Learn about new guidance for patients with microsatellite stable or proficient mismatch repair disease:

🔬 The recent phase 2 BEER BTC trial by Anant Ramaswamy and colleagues examined the use of bevacizumab-erlotinib as a switch maintenance therapy for chemotherapy-responsive biliary tract cancer. 👉 Learn how the combo can improve PFS rates: https://buff.ly/3yXyxte

💉 Trastuzumab deruxtecan has provided encouraging activity in patients with treatment-refractory HER2+ RAS and BRAF wild-type metastatic colorectal cancer. 🔎 As the beneficial effects of this treatment warrant further investigation into dose optimization and antitumor activity, researchers evaluated the effects of 2 different doses of the treatment:

🚨 The FDA has just accepted the supplemental Biologics License Application for nivolumab (Opdivo) plus ipilimumab (Yervoy) as a potential first-line treatment for adult patients with unresectable hepatocellular carcinoma. 👉 The decision was based on encouraging results from the phase 3 CheckMate-9DW study:

🧪 Watch Wafik S. El-Deiry, MD, PhD, FACP of Brown Medicine discuss the use of 5FU in future gastrointestinal cancer studies. 🔬Learn how regorafenib and TAS102 reduces ALDH1 expression in HT29 cells: https://lnkd.in/eMm9Gkrh

❗️ The FDA has accepted a supplemental new drug application from Exelixis for #cabozantinib to treat patients with gastroenteropancreatic neuroendocrine tumors. 👉 Learn how the phase 3 CABINET trial showed the drug's ability to boost PFS:

💊 Results of the NAPOLI-1 trial showed the benefits of nanoliposomal irinotecan with #fluorouracil and #leucovorin for pancreatic ductal adenocarcinoma. 📋 Learn how the new NALIRICC trial has examined the combination in patients with previously-treated #cholangiocarcinoma:

🔎 In patients with mucinous appendiceal adenocarcinoma, GNAS mutations can estimate metastatic burden and treatment resistance. 📋 New research has sought to determine the effects of GNAS variants on pan-cancer clinicopathology:

⭐ Dan Kaufman, professor of medicine at UC San Diego, discusses recent research on transforming growth factor beta and how it is linked to the development of hepatocellular carcinoma. 👉 Learn more about how TGF-β inhibition works in conjunction with anti-HCC CARs to promote anti-tumor activity: https://lnkd.in/e3Zjg7K6

🧬 While germline testing is recommended for patients with pancreatic ductal adenocarcinoma, many do not undergo testing. 👉 A new clinical point of care workflow at an academic medical center has been developed and tested to determine how the system can benefit from routine clinical practice for patients with PDAC: